Europeiska unionen - estniska - EMA (European Medicines Agency)

gedeon richter plc. - teriparatiid - osteoporoos - kaltsiumi homöostaas - terrosa on näidustatud täiskasvanutel. osteoporoosi ravi postmenopausis naistel ja meestel, kellel on suurem luumurdude risk. postmenopausaalsetel naistel on selgelt ja selgroogsete luumurdude, kuid mitte puusaluumurdude esinemissageduse märkimisväärne vähenemine. ravi osteoporoosi seostatakse pidevat süsteemset glükokortikoidi ravi naiste ja meeste suurenenud risk luumurdude.

Estland - estniska - Ravimiamet

portfarma ehf. - ropinirool - toimeainet prolongeeritult vabastav tablett - 8mg 90tk; 8mg 30tk; 8mg 42tk; 8mg 7tk; 8mg 21tk

Estland - estniska - Ravimiamet

portfarma ehf. - ropinirool - toimeainet prolongeeritult vabastav tablett - 2mg 90tk; 2mg 7tk; 2mg 100tk; 2mg 21tk; 2mg 28tk; 2mg 30tk

Estland - estniska - Ravimiamet

hospira uk limited - oksaliplatiin - infusioonilahuse pulber - 5mg 1ml 100mg 1tk

Estland - estniska - Ravimiamet

portfarma ehf. - ropinirool - toimeainet prolongeeritult vabastav tablett - 3mg 84tk; 3mg 42tk; 3mg 7tk; 3mg 21tk; 3mg 100tk

Estland - estniska - Ravimiamet

accord healthcare b.v. - aripiprasool - suus dispergeeruv tablett - 15mg 56tk; 15mg 98tk; 15mg 30tk; 15mg 14tk; 15mg 28tk

Estland - estniska - Ravimiamet

portfarma ehf. - ropinirool - toimeainet prolongeeritult vabastav tablett - 4mg 90tk; 4mg 7tk; 4mg 84tk; 4mg 100tk; 4mg 30tk; 4mg 28tk

Europeiska unionen - estniska - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Europeiska unionen - estniska - EMA (European Medicines Agency)

theramex ireland limited - teriparatiid - osteoporoos - kaltsiumi homöostaas - livogiva is indicated in adults. osteoporoosi ravi postmenopausis naistel ja meestel, kellel on suurem luumurdude risk. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. ravi osteoporoosi seostatakse pidevat süsteemset glükokortikoidi ravi naiste ja meeste suurenenud risk luumurdude.

Europeiska unionen - estniska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastilised ained - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.